Accelerating Innovation at Leica Biosystems

Significant Opportunity in Molecular Diagnostics • BEST-IN-CLASS MOLECULAR DX OFFERING Differentiated position at critical, point-of-care settings • Workflow + speed + accuracy • Broadest test menu: >35 OUS, >20 in the US MOLECULAR DIAGNOSTICS MARKET PENETRATION Cepheid. < 50% < 50% Cepheid GeneXpertⓇ Systems & test cartridge GeneXpert Xpert Xpress SAS Cov-2/RSV < 15% <15% HGM Developed Markets US - POL US - small/mid- sized hospitals Cepheid uniquely positioned for long-term growth opportunity DANAHER

View entire presentation